Eribulin in advanced liposarcoma and leiomyosarcoma

ABSTRACT

Introduction: The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line.

Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in STS is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects.

Expert commentary: Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile. Further studies are required to better understand the precise mechanism of action of this agent and potential role in combination schedules.

KEYWORDS:

• Eribulin
• liposarcoma
• histology-driven therapy
• overall survival
• soft tissue sarcomas
• eribulin biological effects

Declaration of interest

RL Jones has acted as a consultant for Eisai, Lilly, Merck, JJ, TRACON, Morphotek, Immune Design, Adaptimmune and Immodulon. S Chawla has acted as a consultant ad sat on the advisory board for Amgen, Eisai, Johnson & Johnson, Janssen, Novartis, Threshold, Pharmamar, TRACON and Morphotek. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This manuscript has received funding from Eisai.